206 related articles for article (PubMed ID: 35154623)
21. Incidence and predisposing factors of infection in patients treated with hypomethylating agents.
Kirkizlar TA; Kirkizlar O; Demirci U; Umut A; Iflazoglu H; Umit EG; Demir AM
Leuk Res; 2023 Apr; 127():107043. PubMed ID: 36801588
[TBL] [Abstract][Full Text] [Related]
22. Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes.
Dahlén T; Kalin M; Cederlund K; Nordlander A; Björkholm M; Ljungman P; Blennow O
Eur J Haematol; 2016 Feb; 96(2):175-80. PubMed ID: 25880378
[TBL] [Abstract][Full Text] [Related]
23. Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy: A Prospective Observational Study From the Acute Leukaemia French Association (ALFA) Group.
Michallet M; Sobh M; Morisset S; Deloire A; Raffoux E; de Botton S; Caillot D; Chantepie S; Girault S; Berthon C; Bertoli S; Lepretre S; Leguay T; Castaigne S; Marolleau JP; Pautas C; Malfuson JV; Veyn N; Braun T; Gastaud L; Suarez F; Schmidt A; Gressin R; Bonmati C; Celli-Lebras K; El-Hamri M; Ribaud P; Dombret H; Thomas X; Bergeron A
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):311-318. PubMed ID: 34895843
[TBL] [Abstract][Full Text] [Related]
24. Exposure-Response Relationship of Posaconazole Suspension in Theprophylaxis of Invasive Fungal Infections in Patients with Acute Myeloid Leukemia.
Sengar M; Jain H; D'souza S; Kannan S; Mokal S; Gurjar M; Ambotkar M; Sharma N; Boppanna M; Gota V
Indian J Hematol Blood Transfus; 2023 Apr; 39(2):200-207. PubMed ID: 37006974
[TBL] [Abstract][Full Text] [Related]
25. The Outcome of Antifungal Prophylaxis with Posaconazole in Patients with Acute Myeloid Leukemia: A Single-Center Study.
Özkocaman V; Özkalemkaş F; Seyhan S; Ener B; Ursavaş A; Ersal T; Kazak E; Demirdöğen E; Mıstık R; Akalın H
Turk J Haematol; 2018 Nov; 35(4):277-282. PubMed ID: 30047484
[TBL] [Abstract][Full Text] [Related]
26. A Prospective Study to Evaluate the Effect of Therapeutic Drug Monitoring-Based Posaconazole Prophylaxis on Invasive Fungal Infection Rate During Acute Myeloid Leukemia Induction Therapy.
Boppana M; Sengar M; Jain H; Gurjar M; Ambotkar M; Gota V; Bonda A; Bagal B; Thorat J; Gokarn A; Nayak L; Shetty N; Baheti A; Mokal S; Kannan S; Shetty A; Eipe T
Indian J Hematol Blood Transfus; 2024 Apr; 40(2):204-212. PubMed ID: 38708158
[TBL] [Abstract][Full Text] [Related]
27. [Economic evaluation of posaconazole in prophylaxis of invasive fungal infections in Italian neutropenic patients with acute myeloid leukaemia or myelodysplastic syndrome].
Lazzaro C
Infez Med; 2010 Jun; 18(2):91-103. PubMed ID: 20610931
[TBL] [Abstract][Full Text] [Related]
28. Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: A randomized study.
Epstein DJ; Seo SK; Huang YT; Park JH; Klimek VM; Berman E; Tallman MS; Frattini MG; Papanicolaou GA
J Infect; 2018 Sep; 77(3):227-234. PubMed ID: 29746955
[TBL] [Abstract][Full Text] [Related]
29. Real-world effectiveness of antifungal prophylaxis with posaconazole as the primary agent in patients with haematological malignancies.
Strand AM; Alexander BD; Sarpong E; Wong JR; Engemann A; Rizzieri D; Wu Y; Johnson MD
Mycoses; 2022 Nov; 65(11):1050-1060. PubMed ID: 35816393
[TBL] [Abstract][Full Text] [Related]
30. Hypomethylating agents (HMAs) show benefit in AML rather than in intermediate/high-risk MDS based on genetic mutations in epigenetic modification (EMMs): from a retrospective study.
Wang R; Xu Y; Wang B; Wang H; Wang M; Jing Y; Gao X; Yu L
Ann Hematol; 2024 Jan; 103(1):61-71. PubMed ID: 37926751
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax.
Chen EC; Liu Y; Harris CE; Winer ES; Wadleigh M; Lane AA; Vedula RS; Lindsley RC; Copson KM; Charles A; Marty F; Neuberg D; DeAngelo DJ; Stone RM; Luskin MR; Issa NC; Garcia JS
Leuk Lymphoma; 2022 Aug; 63(8):1934-1941. PubMed ID: 35289704
[TBL] [Abstract][Full Text] [Related]
32. Posaconazole versus voriconazole as antifungal prophylaxis during induction therapy for acute myelogenous leukemia or myelodysplastic syndrome.
Phillips K; Cirrone F; Ahuja T; Siegfried J; Papadopoulos J
J Oncol Pharm Pract; 2019 Mar; 25(2):398-403. PubMed ID: 30319061
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia.
Mattiuzzi G; Yilmaz M; Kantarjian H; Borthakur G; Konopleva M; Jabbour E; Brown Y; Pierce S; Cortes J
J Infect Chemother; 2015 Sep; 21(9):663-7. PubMed ID: 26141814
[TBL] [Abstract][Full Text] [Related]
34. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Mellinghoff SC; Panse J; Alakel N; Behre G; Buchheidt D; Christopeit M; Hasenkamp J; Kiehl M; Koldehoff M; Krause SW; Lehners N; von Lilienfeld-Toal M; Löhnert AY; Maschmeyer G; Teschner D; Ullmann AJ; Penack O; Ruhnke M; Mayer K; Ostermann H; Wolf HH; Cornely OA
Ann Hematol; 2018 Feb; 97(2):197-207. PubMed ID: 29218389
[TBL] [Abstract][Full Text] [Related]
35. Cost effectiveness of posaconazole in the prophylaxis of invasive fungal infections in acute leukaemia patients for the French healthcare system.
Michallet M; Gangneux JP; Lafuma A; Herbrecht R; Ribaud P; Caillot D; Dupont B; Moreau P; Berger P; O'Sullivan AK
J Med Econ; 2011; 14(1):28-35. PubMed ID: 21175376
[TBL] [Abstract][Full Text] [Related]
36. High rate of invasive fungal infections during early cycles of azacitidine for patients with acute myeloid leukemia.
Wang ST; Chou CH; Chen TT; Lin CC; Bai LY; Yeh SP; Ho MW; Lien MY
Front Cell Infect Microbiol; 2022; 12():1012334. PubMed ID: 36530436
[TBL] [Abstract][Full Text] [Related]
37. Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent.
On S; Rath CG; Lan M; Wu B; Lau KM; Cheung E; Alegria W; Young R; Tan M; Kim C; Phun J; Patel N; Mannis G; Logan AC; Kennedy V; Goodman A; Taplitz RA; Young PA; Wen R; Saunders IM
Br J Haematol; 2022 Apr; 197(1):63-70. PubMed ID: 35174480
[TBL] [Abstract][Full Text] [Related]
38. Invasive Fungal Infections in Children with Leukemia: Clinical Features and Prognosis.
Sezgin Evim M; Tüfekçi Ö; Baytan B; Ören H; Çelebi S; Ener B; Üstün Elmas K; Yılmaz Ş; Erdem M; Hacımustafaoğlu MK; Güneş AM
Turk J Haematol; 2022 Jun; 39(2):94-102. PubMed ID: 34792308
[TBL] [Abstract][Full Text] [Related]
39. Economic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in Sweden.
Lundberg J; Höglund M; Björkholm M; Åkerborg Ö
Clin Drug Investig; 2014 Jul; 34(7):483-9. PubMed ID: 24820968
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of posaconazole compared with standard azole therapy for prevention of invasive fungal infections in patients at high risk in Switzerland.
Greiner RA; Meier Y; Papadopoulos G; O'Sullivan AK; Imhof A
Oncology; 2010; 78(3-4):172-80. PubMed ID: 20414005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]